- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.08. | Boundless Bio, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 24.08. | Biotech Stocks At 52-Week Highs - Eloxx Pharmaceuticals, Prelude Therapeutics, argenX, Boundless Bio, Corcept Therapeutics | 675 | AFX News | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 21, 2026, as new trials continued enrolment and companies released positive clinical research data.Eloxx... ► Artikel lesen | |
| BOUNDLESS BIO Aktie jetzt für 0€ handeln | |||||
| 07.08. | Boundless Bio, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 25.06. | Boundless Bio And Serapha Bio Announce Merger And $230 Million Private Placement | 3 | pulse2.com | ||
| 23.06. | Serapha Bio takes flight from Boundless Bio merger with $230M and gene-editing prospect from China | 1 | FierceBiotech | ||
| 23.06. | Boundless Bio Shares Surge 77% On Merger Agreement With Serapha Bio | 1 | RTTNews | ||
| 23.06. | Boundless Bio Aktie steigt nach Fusionsankündigung mit Serapha Bio sprunghaft an | 10 | Investing.com Deutsch | ||
| 23.06. | Boundless Bio Merges Serapha Bio; Raise $230 Mln In Private Placement; Stock Down | 1 | RTTNews | ||
| 23.06. | Boundless Bio to merge with Serapha Bio in reverse merger; shares surge | 1 | Seeking Alpha | ||
| 23.06. | Boundless Bio to merge with Serapha Bio in reverse merger deal | 10 | Investing.com | ||
| 23.06. | Boundless Bio, Inc.: Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement | 729 | GlobeNewswire (Europe) | Combined company to operate as Serapha Bio and to advance Serapha's potential best-in-class in vivo base editing program for Alpha-1 Antitrypsin Deficiency Serapha's lead program SERP-01 targets the... ► Artikel lesen | |
| 17.06. | Boundless Bio: Hauptversammlung wählt Direktoren und bestätigt Wirtschaftsprüfer | 1 | Investing.com Deutsch | ||
| 17.06. | Boundless Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.05. | Boundless Bio GAAP EPS of -$0.60 | 2 | Seeking Alpha | ||
| 08.05. | Boundless Bio, Inc.: Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights | 332 | GlobeNewswire (Europe) | Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 $93 million in cash provides runway through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, May 08, 2026... ► Artikel lesen | |
| 08.05. | Boundless Bio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 08.05. | Boundless Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.04. | Boundless Bio presents preclinical data on cancer therapy BBI-940 | 2 | Investing.com | ||
| 17.04. | Boundless Bio, Inc.: Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 13.04. | Boundless Bio, Inc. - 8-K, Current Report | 5 | SEC Filings |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 83,80 | +0,18 % | BioNTech SE: Neue Daten zu Gotistobart zeigten annähernde Verdopplung des medianen Gesamtüberlebens im Vergleich zur Standardchemotherapie bei Patientinnen und Patienten mit zuvor behandeltem Plattenepithelkarzinom der Lunge | Gotistobart zeigte weiterhin Potenzial als chemotherapiefreie Monotherapie zur Reaktivierung der Anti-Tumor-Immunität in bereits vorbehandelten Patientinnen und Patienten mit Plattenepithelkarzinom... ► Artikel lesen | |
| EVOTEC | 2,914 | +1,11 % | Neue Angriffspunkte gegen Krebs! Warum Vidac Pharma, BioNTech und Evotec Aufmerksamkeit verdienen! | Krebszellen nutzen ausgeklügelte Schutzmechanismen, entziehen sich dem Immunsystem und programmieren ihren eigenen Stoffwechsel um. Diese Mechanismen werden nun verstärkt zur Zielscheibe von Biotechgesellschaften.... ► Artikel lesen | |
| AMGEN | 335,15 | -0,16 % | Amgen: FDA Approves Update To IMDELLTRA Prescribing Information, Cuts Monitoring Time For Two Doses | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced the FDA approved an update to the IMDELLTRA Prescribing Information that substantially reduces the recommended monitoring time for the first... ► Artikel lesen | |
| NOVAVAX | 8,670 | -1,37 % | Novavax: Langfristige Aussichten im Spannungsfeld von Innovation und Konkurrenz | ||
| BIOGEN | 189,04 | +0,74 % | Biogen Inc.: Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN | EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, based... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 10,900 | +0,37 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| VIVOSIM LABS | 0,223 | -1,67 % | VivoSim Labs, Inc.: VivoSim Labs Unveils New NAMkind Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs | ||
| INOVIO PHARMACEUTICALS | 1,077 | +9,40 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| CLINUVEL | 5,022 | -1,26 % | CLINUVEL PHARMACEUTICALS LIMITED: CLINUVEL date of Annual General Meeting | ||
| VIKING THERAPEUTICS | 25,100 | -0,59 % | Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic. | ||
| INTELLIA THERAPEUTICS | 10,360 | -2,08 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million | CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen | |
| TEMPUS AI | 67,70 | -0,09 % | Tempus AI stock is soaring: does it have more upside to go? | ||
| BIOCRYST PHARMACEUTICALS | 7,490 | 0,00 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen | |
| ABIVAX | 90,75 | -2,89 % | Abivax Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call | ||
| BIOMARIN PHARMACEUTICAL | 56,08 | +0,75 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors | SAN RAFAEL, Calif., Sept. 14, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that the company has appointed Robert Plenge, M.D., Ph.D.... ► Artikel lesen |
Das Unternehmen BOUNDLESS BIO INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,020 (-0,71 %) liegt der Kurs bei 2,790 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BOUNDLESS BIO INC finden Sie auf Wallstreet Online.